What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Rampril (brand name: Altace), an angiotensin-converting enzyme inhibitor used to treat high blood pressure and myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3
Significance of the study:
Clopidogrel has been shown to shown to treat myocardial disorders. However, its mechanism of action is far from understood.
This study suggests, for the first time, that Rampril, by increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1). Thus, pharmacological formulations encompassing “Rampril or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2).
Details of the research findings:
Idea Proposed/Formulated by:
Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How Rampril decreases the expression of Notch3 and its target gene
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Molecular therapy for pulmonary arterial hypertension: Rampril (brand name: Altace), an angiotensin-converting enzyme inhibitor used to treat high blood pressure and myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 29/January/2018, 10.42 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at email@example.com